Orano Med, Orano’s medical subsidiary, is combining biotechnology and nuclear energy to develop targeted cancer treatments using the unique properties of lead-212 (212Pb).
Its work is fueling the hope that the international medical community will move toward less toxic, more effective treatments for patients with limited treatment options.
Lead-212 is a very rare radioactive isotope that comes from thorium. Orano’s expertise in cutting-edge nuclear technologies has made it possible to develop a unique process that contributes to the extraction and purification of lead-212. This rare metal is used in the development of several promising targeted cancer treatments referred to as “Targeted Alpha Therapy”.